Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clinuvel Pharmaceuticals ( (AU:CUV) ) has shared an update.
Clinuvel Pharmaceuticals reported its ninth consecutive year of revenue growth and profit, with a 10% increase in revenues to $105.3 million for the fiscal year ending June 30, 2025. The company’s net profit before tax rose by 2% to $51.6 million, driven by robust demand for SCENESSE® and higher interest income. Despite a 20% rise in expenses due to increased personnel and clinical development costs, Clinuvel maintained a strong financial position with a 22% increase in cash reserves to $224.1 million. This financial strength enables the company to self-finance its diversification plans and manage risks in a volatile macroeconomic environment.
The most recent analyst rating on (AU:CUV) stock is a Buy with a A$13.00 price target. To see the full list of analyst forecasts on Clinuvel Pharmaceuticals stock, see the AU:CUV Stock Forecast page.
More about Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for severe skin disorders. Its primary product, SCENESSE® (afamelanotide 16mg), is used to treat erythropoietic protoporphyria (EPP) patients, primarily in Europe and the USA. The company is also advancing its clinical program for vitiligo.
Average Trading Volume: 98,694
Technical Sentiment Signal: Hold
Current Market Cap: A$686.7M
Find detailed analytics on CUV stock on TipRanks’ Stock Analysis page.